etoposide + anlotinib + envafolimab

This combination therapy regimen consists of the cytotoxic chemotherapy agent etoposide, the multi-targeted tyrosine kinase inhibitor anlotinib, and the PD-L1-directed monoclonal antibody envafolimab. It is currently being evaluated in a Phase II clinical trial as a first-line treatment for elderly patients with extensive-stage small cell lung cancer (ES-SCLC). Etoposide acts by inhibiting topoisomerase II, leading to DNA strand breaks and cell death. Anlotinib provides anti-angiogenic effects by blocking signaling through VEGFR, PDGFR, FGFR, and c-KIT pathways. Envafolimab is a unique single-domain antibody (nanobody) that inhibits the PD-1/PD-L1 immune checkpoint, thereby enhancing the anti-tumor immune response. This triple-combination approach aims to improve clinical outcomes by simultaneously targeting tumor cell proliferation, blood vessel formation, and immune evasion.

Brand names

FukanghuaVepesid

Other names

toposide + anlotinib + envafolimabOral etoposide combined with anlotinib and envafolimab